source
- Bristol Myers' lung drug admilparant meets Phase 3 goal at low dose, high dose falls shortBristol Myers Squibb reported that its experimental idiopathic pulmonary fibrosis therapy admilparant achieved its primary endpoint in a Phase 3 trial, showing a statistically significant slowing o…
- Tortugas Neuroscience's obuprazine shows significant improvement in phase 2b schizophrenia trial in ChinaTortugas Neuroscience, a biotech founded by former Sage Therapeutics staff with $106 million in funding, reported positive data from a phase 2b study of its schizophrenia candidate obuprazine, lice…